Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Impact of a Minimally Invasive Approach to Laparoscopic Hysterectomy on Postoperative Recovery (MIN-HYSTER)

21 ottobre 2021 aggiornato da: Institut Mutualiste Montsouris

Background Managing perioperative stress, including endocrino-metabolic changes and, inflammatory and pain responses, is a major challenge to improve patient's recovery. Currently, minimally invasive surgical procedures combined with multimodal analgesia are commonly used to increase the quality of postoperative period.

Purpose To demonstrate that a minimally invasive approach including low insufflation pressure and minitrocars in laparoscopic hysterectomy improves postoperative recovery and reduces pain stimulation and opioid consumption in comparison with a conventional approach.

Methods After informed consent, all patients scheduled for a laparoscopic hysterectomy including those with carcinologic disease will be part of this monocentric prospective randomized double-blinded study.

At admission in our outpatient unit, patients will have to fill the Post-operative Quality of Recovery Scale assessment form, before to be randomized into one of the following two groups:

  • Conventional approach: laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
  • Mini-invasive approach : laparoscopic surgery using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.

Both groups will have general anesthesia with a deep neuromuscular blockade (TOF = 0 at the thumb adductor) and will benefit of our enhanced recovery program. Patients and evaluators will be blind regarding the allocated group.

The primary outcome is a comparison of the postoperative recovery between the two groups through the Post-operative Quality of Recovery Scale.This evaluation will include pain data, nausea/vomiting evaluation and cognitive function 6 hours after surgery.

Secondary outcomes are morphine consumption surgical comfort and patient satisfaction.

Panoramica dello studio

Descrizione dettagliata

Introduction About 43,000 hysterectomies were performed in France in 2016 half of them as a laparoscopic procedure. Compared to vaginal hysterectomy, laparoscopic surgery decreases postoperative pain and hospital length of stay [PubMed ID: 25524534 ]. Laparoscopic hysterectomy is also the most common surgical technique in the USA within enhanced recovery after surgery programs (ERAS)[2]. However, postoperative pain is still an important issue and results in most of the early re-admissions [3]. In addition, control of intraoperative stress, including painful stimuli, but also endocrine-metabolic and inflammatory responses is a major component of patient's recovery improvement. Reducing length of stay can lead to a possible outpatient surgery with a high level of quality and safety.

Hysterectomy in outpatient setting is barely done in France (0.1% in 2012 and 1.5% in 2017) compare to USA (more than 50%) so there is still a significant scope of improvement [2].

Many parameters need to be controlled to reduce perioperative stress [4,5]. Francophone teams showed that the use of mini-invasive techniques such as low and stable abdominal insufflation pressure is an important factor regarding pain and inflammation after gynecological surgery [6,7]. Furthermore to reduce parietal and peritoneal injuries can be achieved by using very small trocars while allowing surgery to be performed in good conditions [8,9]. Some teams have combined these two techniques with promising results in abdominal surgery [10].

The choice of anesthesia technic within an ERAS program that include quick elimination drugs, vascular filling monitoring and optimization, prevention of hypothermia and postoperative nausea/vomiting (PONV), as well as a multimodal analgesia, including loco-regional analgesia allow a faster postoperative recovery after pelvic surgery [11, 12]. Among these parameters, post-operative pain management is a major component. It has been demonstrated that pain prolongs surgical stress, delays mobilization and full recovery. Opioid medication therapy results in many adverse effects (PONV, sedation) and delays postoperative recovery[12]. Furthermore, availability of opioids at home is currently a real public health issue[13]. After a conventional hysterectomy use of opioids is almost systematic[14]. Therefore the challenge is to provide effective analgesia with the minimum of opioids use. Anesthesia with a deep neuromuscular blockade allows a low peritoneal pressure while maintaining optimal surgical comfort[15].

Hypothesis A mini-invasive approach of laparoscopic hysterectomy, combining mini-trocars and low pneumoperitoneum pressure would improve quality of post-operative recovery and reduce length of stay in the hospital allowing the procedure to be performed as outpatient surgery.

Purposes

  • Primary goal: to demonstrate that a mini-invasive laparoscopic hysterectomy compared to a conventional approach improves the PQRS score.
  • Secondary goal:

To assess intraoperative pain intensity using the Analgesia Nociception Index (ANI) and whether minimally invasive surgery reduces the use of per- and postoperative opioids, PONV and patient satisfaction.

Methods This randomized prospective study will be carried out according to CONSORT methodological standards[17].

Information and recruitment During the pre-operative clinic, surgeon will check patient's eligibility regarding the inclusion criteria and patients will receive oral and written inform consent about the study. During anesthesia clinic, eligibility for ambulatory surgery will be confirmed and informed consent will be obtained. Throughout the duration of the study (24 hours), the patient will not be able to be included in any other research protocol that could affect her post-operative recovery.

Population After informed consent, all eligible patients undergoing laparoscopic hysterectomy surgery for benign or malignant affections will be included. Inclusion criteria are: stable ASA (American Society of Anesthesiologists )score <3, no contraindication to take nonsteroidal anti-inflammatory drugs , absence of chronic pain, perfect understanding of post-operative psycho-motor assessment, presence of an attendant, distance between home and hospital allowing a possible quick readmission and acceptance to respect all the given medical instructions.

Patients will be systematically excluded in case of laparo-conversion and surgical or anesthetic complication.

Randomization and PQRS assessment:

After admission in the day surgery unit all patient included in the study will fill a PQRS form before to be randomized in one of the two groups. Randomization and intraoperative patient care will not be achieved by the PQRS assessor.

Randomization into one of the two arms will be done by using a remote computer randomization system :

  • Conv group conventional approach : laparoscopic surgery using standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
  • Mini-inv group mini-invasive approach: laparoscopic surgery using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.

Both group will have an anesthesia with a deep neuromuscular blockade (TOF = 0 at the thumb adductor).

Neither the patient nor the evaluator will be aware of the randomization group.

- The pre-operative and H6 PQRS score will be collected by an anesthesiologist not involve in patient care either per or post operatively up to 24h after surgery.

Perioperative management All patient will benefit of our ERAS protocol: fasting allowing the use of drinks up to 2 hours before anesthesia[16], general anesthesia with oro-tracheal intubation and protective mechanical ventilation (current tidal volume between 6-8 ml/kg of ideal weight and peep at 5 cmH2O) with a mixture of air and oxygen (50/50) and multimodal analgesia with intravenous lidocaine infusion (1,5 mg/kg bolus immediately after induction followed by a continuous infusion of 1,5 mg/kg/h stopped 20 min before the end of the procedure. Anesthesia will be performed according to our department protocol : induction and maintenance of anesthesia by propofol/remifentanil operated by target controlled intravenous anesthesia system (TIVA); anesthetic depth monitored with a bispectral index (BIS) between 45 and 55; per-operative analgesia provided by remifentanil with a brain concentration objective 0,35 ng/L for induction. Quality of analgesia will be monitored through the Analgesia Nociception Index (ANI). Remifentanil brain concentration objective will be changed to keep ANI in a range of 50 to 70. Depth of neuromuscular block with atracurium will be monitored by train-of-four. Neuromuscular blockade will be antagonized at the end of surgery according to the recommended procedure [17].

Routine analgesia will be started 20 minutes before the end of the procedure : paracetamol 1 g and ketoprofen up to 100 mg according to age and kidney function. Intraperitoneal (20 ml) and trocars orifices (10 ml) infiltration will be achieved by 2 mg/ml ropivacaine at the end of the procedure. In addition, heated blanket will be used to prevent hypothermia and central temperature will be monitored with esophageal temperature sensor. Dexamethasone 8 mg and droperidol 0.625 mg will be given to prevent PONV. Fluid therapy will be limited to 2 ml/kg/h besides blood loss compensation with a balanced solution of Ringer-Lactate. No urinary catheter will be placed.

In the Post-anesthesia care unit (PACU), pain at rest and cough will be assessed using a verbal numeric scale (VNS) between 0 (no pain) and 10 (worst pain imaginable). Patients will receive morphine intravenously (3 mg every 5 min) if the VNS level is >3/10. In the case of PONV, intravenous ondansetron 4 mg will be given.

Patients will be allowed to feed and intravenous catheter will be removed as soon as they leave the PACU. Patients will be invited to walk as soon as they can. Preventive anticoagulation with enoxaparin will be started 6 hours postoperatively. Postoperative analgesia will be managed by a combination of paracetamol 500 mg and opium 20 mg and ketoprofen 50 mg every 6 hours.

Patient will be discharged from the day surgery unit according to a "Chung score" > 9. Decision to keep the patient overnight will be made by the surgeon and anesthesiologist in charge of the patient regardless of the study or randomization group.

Twenty four hours after surgery, outpatient will be called at home and inpatient seen in her room by a research assistant to answer to a satisfaction survey and to assess postoperative pain intensity and by mouth morphine consumption.

Outcomes evaluation The primary outcome is a comparison between the two groups of immediate postoperative recovery as determined by the PQRS score [18], applied at the 6th postoperative hour (pain score, PONV and cognitive recovery).

The secondary outcomes are :

  • intraoperative intensity of nociceptive stimulation measured by the intraoperative opioids consumption (remifentanil) according to the Analgesia Nociception Index (ANI) [19]
  • postoperative pain intensity at rest, cough and walk (if possible) and based on the Verbal Numeric Scale (VNS) at H2, H6 and H24 post-operative, intravenous morphine consumption in PACU and by mouth opioids (morphine sulfate) during the first 24 post-operative hours
  • Incidence of PONV
  • Percentage of patients who reached the preoperative PQRS score at H6
  • Surgical comfort on the Leiden scale [20]
  • Surgery duration, length of stay in PACU (Aldrete score/15min)
  • Number of patients with PADSS scores < 9 at H2 and H6 [21]
  • Number of outpatients
  • Bowel movement at H24 post-operative
  • Number of patients who returned to hospital after discharge (or requiring medical contact) within 7 days after surgery.
  • Patient satisfaction (EVAN score) [22]
  • Potential adverse events

Statistical analysis The number of patients required to show a 5-point difference in the PQRS score, with a risk α of 5% and a risk β of 20%, taking into account a baseline score in the Conv group of 30 +/- 5 at H6 is 31 patients per group. With 20% of patients included but not evaluable or with deviations from protocol, 37 patients per group should be included. The statistical analysis will be carried out on a per-protocol basis and with intention to treat. It will be based on the t-Student test for the main criterion (PQRS) and Mann-Whitney or Chi-2 tests for other parameters depending on the type of parameter.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

67

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Responsable of Clinical Research Unit
  • Numero di telefono: + 33 156616705
  • Email: isabelle.sauret@imm.fr

Luoghi di studio

      • Paris, Francia, 75014
        • Reclutamento
        • Insitut Mutualiste Montsouris
        • Contatto:
          • M.D.,Ph.D.
        • Investigatore principale:
          • Karim BOUATTOUR

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • programmed to laparoscopic hysterectomy
  • stable ASA score <3
  • no contraindication to take nonsteroidal anti-inflammatory drugs
  • absence of chronic pain
  • perfect understanding of post-operative psycho-motor assessment
  • presence of an attendant
  • distance between home and hospital allowing a possible quick readmission
  • acceptance to respect all the given medical instructions.

Exclusion Criteria:

  • laparo-conversion and surgical or anesthetic complication.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Conventional approach
Conventional approach to laparoscopic hysterectomy
laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
Sperimentale: Mini-invasive approach
Mini-invasive approach to laparoscopic hysterectomy
using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
immediate postoperative recovery
Lasso di tempo: 6th post-operative hour
determined by the Post Operative Quality of recovery scale PQRS (pain score, PONV and cognitive recovery)
6th post-operative hour

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
intraoperative intensity of nociceptive stimulation
Lasso di tempo: 4th induction hour
measured by the intraoperative opioids consumption (remifentanil) according to the Analgesia Nociception Index (ANI) in microgram.
4th induction hour
postoperative pain intensity: Verbal Numeric Scale (VNS)
Lasso di tempo: 2nd, 6th and 24th post-operatives hours
measured at rest, cough and walk (if possible) and based on the Verbal Numeric Scale (VNS) from 0 to 10.
2nd, 6th and 24th post-operatives hours
Patient satisfaction: EVAN G score
Lasso di tempo: 24th post-operative hour
EVAN G score.
24th post-operative hour
rate of return after discharge
Lasso di tempo: Day 7 after discharge
% of patients who returned to hospital after discharge.
Day 7 after discharge
Bowel movement
Lasso di tempo: Day 1 after discharge
% of patients who had bowel movement in each group
Day 1 after discharge
Number of outpatients
Lasso di tempo: Day 1 after discharge
rate of outpatients (%)
Day 1 after discharge
PADSS scores
Lasso di tempo: 2nd and 6th post-operatives hours
rate of patients who had PADSS score <9.
2nd and 6th post-operatives hours
Surgery duration, length of stay in PACU
Lasso di tempo: 4th post-operative hour
In hh:mn
4th post-operative hour
Surgical comfort
Lasso di tempo: 6th post-operative hour
Leiden scale
6th post-operative hour
intravenous morphine consumption
Lasso di tempo: 2nd, 6th and 24th post-operatives hours
measured in PACU and by mouth opioids in mg.
2nd, 6th and 24th post-operatives hours
Incidence of PONV
Lasso di tempo: 2nd, 6th and 24th post-operatives hours
rate of patients with PONV
2nd, 6th and 24th post-operatives hours

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Karim BOUATTOUR, Doctor, Institut Mutualiste Montsouris

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

2 dicembre 2019

Completamento primario (Anticipato)

1 giugno 2023

Completamento dello studio (Anticipato)

1 giugno 2023

Date di iscrizione allo studio

Primo inviato

3 ottobre 2019

Primo inviato che soddisfa i criteri di controllo qualità

21 ottobre 2021

Primo Inserito (Effettivo)

1 novembre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 novembre 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

21 ottobre 2021

Ultimo verificato

1 ottobre 2021

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • ANEST-01-2019

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Conventional approach

Sottoscrivi